MARKET

VRTX

VRTX

Vertex Pharmaceuticals Inc
NASDAQ
523.91
+27.84
+5.61%
Pre Market: 525.00 +1.09 +0.21% 05:42 08/11 EDT
OPEN
539.50
PREV CLOSE
496.07
HIGH
546.17
LOW
519.82
VOLUME
118
TURNOVER
331.78M
52 WEEK HIGH
546.17
52 WEEK LOW
362.50
MARKET CAP
132.79B
P/E (TTM)
30.48
1D
5D
1M
3M
1Y
5Y
1D
Vertex Pharmaceuticals (VRTX) Is Up 11.3% After Raising 2026 Revenue Guidance And CF Outlook Shift – Has The Bull Case Changed?
Simply Wall St · 4h ago
Vertex (VRTX) Q2 2026 Earnings Call Transcript
The Motley Fool · 9h ago
Vertex Pharmaceuticals Inc. Stock Rises 5.6%, Outperforms Peers
Dow Jones · 14h ago
Sionna Therapeutics downgraded to Neutral at Guggenheim after trial miss
TipRanks · 17h ago
Analysts Offer Insights on Healthcare Companies: Jade Biosciences (JBIO), Silence Therapeutics (SLN) and Vertex Pharmaceuticals (VRTX)
TipRanks · 18h ago
Vertex Pharmaceuticals price target raised to $672 from $605 at BofA
TipRanks · 18h ago
Why Sionna Therapeutics Stock Is Crashing 92% to a Record Low
Barron‘s · 19h ago
Vertex Stock (VRTX) Soars 7% as Rival Sionna (SION) Crashes 92% on Failed Drug Trial
TipRanks · 19h ago
More
About VRTX
Vertex Pharmaceuticals Incorporated is a global biotechnology company that invests in scientific innovation to create transformative medicines for people with serious diseases, with a focus on specialty markets. It has seven approved medicines: five that treat the underlying cause of cystic fibrosis (CF), one that treats severe sickle cell disease (SCD) and transfusion dependent beta thalassemia (TDT), and one that treats moderate-to-severe acute pain. Its pipeline includes clinical-stage programs in CF, SCD, beta thalassemia, acute and peripheral neuropathic pain, APOL1-mediated kidney disease, IgA nephropathy and other autoimmune renal diseases and cytopenias, type 1 diabetes, myotonic dystrophy type 1, and autosomal dominant polycystic kidney disease. Its marketed medicines are TRIKAFTA/KAFTRIO (elexacaftor/tezacaftor/ivacaftor and ivacaftor), SYMDEKO/SYMKEVI (elexacaftor/tezacaftor/ivacaftor and ivacaftor), ORKAMBI (lumacaftor/ivacaftor), and KALYDECO (ivacaftor).

Webull offers Vertex Pharmaceuticals Inc stock information, including NASDAQ: VRTX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, VRTX stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading VRTX stock methods without spending real money on the virtual paper trading platform.